Canada markets closed

Abeona Therapeutics Inc. (ABEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1800-0.0400 (-3.28%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.2200
Open1.2000
Bid1.1700 x 1000
Ask1.1800 x 800
Day's Range1.1700 - 1.2200
52 Week Range0.9900 - 3.7900
Volume430,029
Avg. Volume1,007,128
Market Cap119.448M
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.5770
Earnings DateNov. 08, 2021 - Nov. 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • GlobeNewswire

    Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings

    Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board Vishwas Seshadri, Ph.D., M.B.A. to become Chief Executive Officer Brendan M. O’Malley, J.D., Ph.D. promoted to General Counsel, Brian Kevany, Ph.D. promoted to Chief Technical Officer, Scott Nogi, M.B.A., Head of Business Operations to expand role and lead operations at Abeona’s Cleveland facility Regulatory veterans in AAV-based gene therapy, Carl Denny and Kate Imhoff, added to team in prepa

  • GlobeNewswire

    Abeona Therapeutics to Present at Upcoming Investor Conferences

    NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company’s management will present and conduct one-on-one meetings at the following virtual investor conferences: Citi’s 16th Annual BioPharma Virtual Conference on September 8-10, 2021 (one-on-one meetings only).H.C. Wainwright 23rd Annual Global Investment Conference. The pre-recorded presentation will be avai

  • GlobeNewswire

    Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer

    NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as Chief Financial Officer and Principal Financial Officer, effective immediately. Mr. Carr had served as Abeona’s Chief Accounting Officer since January 2019. “I look forward to working together with Ed to meet our near-term clinical and regulatory milestones, as well as set Abeona on a course for lo